explore -WSS

explore

author：hotspot 2025-10-01 02:15:58 - browse：66

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Yancopoulos of Regeneron works to expand Dupixent success

WSS

Steward Health Care expansion into Malta flopped

Readout LOUD podcast, live from the STAT Breakthrough Summit East

U.K. officials, researchers try to ease path for bespoke genetic treatments

SNAP should offer more nutrition education

Virtual care provider acquires bankrupt Pear's prescription apps

SEC charges former device maker CEO with $41 million fraud

entertainment

explore

entertainment

Anesthesiologist group: stop taking Ozempic before surgery

Pregnancy ages women, but effects reverse after delivery

Guidelines to prevent youth baseball injuries need more muscle

Why health care costs have stayed mostly flat since 2010

Anesthesiologist group: stop taking Ozempic before surgery

Mirador, a new biotech startup, launches with $400 million

Hepatitis C has a cure — but many Americans still lack access to it

Steward Health Care expansion into Malta flopped

ChatGPT in medicine: STAT answers readers' burning questions

Texas board proposes rules on abortion law emergency exemption

focus

Medicare drug price negotiation hasn't dried up venture capital

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Prime Medicine, Myeloid Therapeutics clash over genome

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Prime Medicine, Myeloid Therapeutics clash over genome

Medicare Advantage beneficiaries sue Humana over algorithm use

leisure time

explore

focus

knowledge